Despite progress in the control of the triatomine vectors, Bolivia remains the country with the highest Trypanosoma cruzi infection prevalence in the world. The major clinical manifestation is Chagas cardiomyopathy, characterized by a chronic inflammatory process leading to conduction system abnormalities, ventricular arrhythmias, sinus node dysfunction and progressive dilated cardiomyopathy with congestive heart failure. National programs have historically only treated children with Chagas disease, but the impetus for adult treatment has grown significantly in the last 10 years, based on growing patient demand and observational data suggesting that treatment, even in patients with early cardiac morbidity decreases the progression of Chagas heart disease and possibly also mortality. Nevertheless, adult treatment will remain beyond the resources of countries like Bolivia, without an effective algorithm to target those at high risk of heart disease. A reliable early indicator of cardiac risk would allow treatment to be targeted to the 20 to 30% of infected individuals with the highest likelihood of future morbidity and mortality. Biomarkers to detect early Chagas heart disease may reflect early changes in cardiac structure and function, substances such as B-type natriuretic peptide released in response to cardiac disease or a substance such as transforming growth factor- beta1 involved in cardiac pathogenesis at the cellular level. We propose to examine biomarkers in multiple categories simultaneously to allow a comprehensive assessment of their relative utility, individually and in combination, in a cohort study recruited from (1) hyperendemic villages where >95% of adults have T. cruzi infection and 17% of infected individuals >30 years have electrocardiographic abnormalities characteristic of Chagas cardiomyopathy, (2) a large public hospital in the city of Santa Cruz where we expect >50% of cardiac patients to have Chagas heart disease and (3) a district hospital in the same hyperendemic zone as the communities mentioned above. The major outcome measure will be progression of Chagas cardiomyopathy over a 4-year follow-up period. Because of the extraordinarily high prevalence of infection, this population will be ideal for assessing associations between biomarkers and early Chagas cardiomyopathy.

Public Health Relevance

Chagas disease causes life-threatening heart disease in people in Latin America, but only 20-30% of people with the infection develop heart disease. Currently there is no marker to tell which people develop disease and which do not. The purpose of this grant is to look for the best marker to predict Chagas heart disease.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Cardiovascular and Sleep Epidemiology (CASE)
Program Officer
Rao, Malla R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Public Health & Prev Medicine
Schools of Public Health
United States
Zip Code
Fu, Katherine Yih-Jia; Zamudio, Roxana; Henderson-Frost, Jo et al. (2017) Association of caspase-1 polymorphisms with Chagas cardiomyopathy among individuals in Santa Cruz, Bolivia. Rev Soc Bras Med Trop 50:516-523
Sherbuk, Jacqueline E; Okamoto, Emi E; Marks, Morgan A et al. (2015) Biomarkers and mortality in severe Chagas cardiomyopathy. Glob Heart 10:173-80
Messenger, Louisa A; Miles, Michael A; Bern, Caryn (2015) Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease. Expert Rev Anti Infect Ther 13:995-1029
Levy, Michael Z; Tustin, Aaron; Castillo-Neyra, Ricardo et al. (2015) Bottlenecks in domestic animal populations can facilitate the emergence of Trypanosoma cruzi, the aetiological agent of Chagas disease. Proc Biol Sci 282:
Fernandez, Antonio B; Nunes, Maria Carmo P; Clark, Eva H et al. (2015) Electrocardiographic and echocardiographic abnormalities in Chagas disease: findings in residents of rural Bolivian communities hyperendemic for Chagas disease. Glob Heart 10:159-66
Yager, Jessica E; Lozano Beltran, Daniel F; Torrico, Faustino et al. (2015) Prevalence of Chagas heart disease in a region endemic for Trypanosoma cruzi: evidence from a central Bolivian community. Glob Heart 10:145-50
Alroy, Karen A; Huang, Christine; Gilman, Robert H et al. (2015) Prevalence and Transmission of Trypanosoma cruzi in People of Rural Communities of the High Jungle of Northern Peru. PLoS Negl Trop Dis 9:e0003779
Clark, Eva H; Marks, Morgan A; Gilman, Robert H et al. (2015) Circulating serum markers and QRS scar score in Chagas cardiomyopathy. Am J Trop Med Hyg 92:39-44
Kaplinski, Michelle; Jois, Malasa; Galdos-Cardenas, Gerson et al. (2015) Sustained Domestic Vector Exposure Is Associated With Increased Chagas Cardiomyopathy Risk but Decreased Parasitemia and Congenital Transmission Risk Among Young Women in Bolivia. Clin Infect Dis 61:918-26
Castillo-Neyra, Ricardo; Chou Chu, Lily; Quispe-Machaca, Victor et al. (2015) The potential of canine sentinels for reemerging Trypanosoma cruzi transmission. Prev Vet Med 120:349-56

Showing the most recent 10 out of 11 publications